Related Experiment Video

Updated: Oct 16, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer

Won-Ji Ryu1, Joo Hyuk Sohn2

  • 1Avison Biomedical Research Center, Yonsei University College of Medicine, Seoul 03722, Korea.

Pharmaceuticals (Basel, Switzerland)
|October 23, 2021
PubMed

Insights

Triple-negative breast cancer (TNBC) is a complex disease with few treatment options. This review explores TNBC

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its molecular heterogeneity.
  • Lack of specific biomarkers limits treatment efficacy, making chemotherapy the primary approach.
  • TNBC tumors lack estrogen receptors, progesterone receptors, and HER2, rendering hormone and HER2-targeted therapies ineffective.

Purpose of the Study:

  • To summarize the molecular heterogeneities observed in triple-negative breast cancer.
  • To identify and discuss potential therapeutic targets for TNBC.
  • To review recently approved and emerging drugs for TNBC treatment.

Main Methods:

  • Literature review of studies on TNBC molecular characteristics.
  • Analysis of current therapeutic strategies and their limitations.
  • Compilation of data on novel drug development and clinical trials for TNBC.

Main Results:

  • TNBC exhibits substantial molecular diversity, impacting treatment response.
  • Several potential therapeutic targets are being investigated beyond traditional chemotherapy.
  • A growing pipeline of novel agents shows promise for improving TNBC outcomes.

Conclusions:

  • Understanding TNBC's heterogeneity is crucial for developing effective targeted therapies.
  • Advances in molecular profiling are paving the way for personalized treatment approaches.
  • Future strategies will likely involve a combination of targeted agents and immunotherapies.
Keywords:
heterogeneitymolecular targetnew drugstriple-negative breast cancer

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

151
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.1K